Feng Chi Biotech Profit Margin

The latest profit margin for 6744.TWO is 7.58% as of June 2026. That compares with 12.15% in the prior-year period — down 37.6% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Feng Chi Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6744.TWO's profit margin moved from 12.15% to 7.58% — a 37.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Feng Chi Biotech's valuation or profitability profile.

Against Healthcare companies, 6744.TWO currently prints 7.58% for profit margin, while the sector average sits near 21.34%. That is roughly 64.5% below the sector mean. Large gaps often invite a closer look at Feng Chi Biotech's growth, margins, and balance sheet.

Profit Margin shows how effectively Feng Chi Biotech converts resources into returns. At 7.58%, 6744.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 12.15% in the prior-year period — down 37.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6744.TWO's profit margin (7.58%), review year-over-year change from 12.15%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.